What type of drug does Canafenib belong to? Detailed explanation of indications and mechanism of action

Encorafenib is a targeted therapy drug that belongs to the BRAF inhibitor class. It is mainly used to treat malignant tumors such as BRAF V600E mutation-positive advanced melanoma and colorectal cancer . BRAF gene mutations are common driver mutations in various cancers, especially in melanoma and some colorectal cancers, where BRAF V600E mutations are particularly common. Canafenib exerts anti-tumor effects by inhibiting the activity of BRAF V600E mutant protein.

BRAF is an important component of the MAPK/ERK signaling pathway and is involved in regulating cell growth, division and survival. In normal cells, BRAF controls the cell cycle and proliferation by regulating the ERK pathway. However, in the case of BRAF V600E mutation, the activity of BRAF protein is overactivated, which can continue to promote abnormal cell proliferation and promote the occurrence and development of tumors even without stimulation from external signals. Therefore, BRAF V600E mutation plays an important role in the development of various cancers.

The mechanism of action of canafenib is to selectively inhibit the kinase activity of BRAF V600E mutant protein, blocking this signaling pathway and reducing the proliferation and survival of tumor cells. Through this mechanism, canafenib can effectively inhibit tumor growth caused by BRAF mutations. Studies have shown that canafenib has significant clinical efficacy in the treatment of patients with BRAF V600E mutation-positive melanoma and colorectal cancer, especially when combined with other drugs.

Usually, canafenib is used in combination with other therapeutic drugs. Common combination drugs includeMEK inhibitors (such as bemetinib) and immune checkpoint inhibitors. Combined use of drugs can enhance the anti-tumor effect, reduce the development of tumor drug resistance, and improve the comprehensiveness and durability of treatment. In patients with melanoma, the treatment regimen of canafenib combined with bimemet has been approved by the FDA. Clinical trials have shown that this combination treatment can significantly improve the progression-free survival (PFS) and overall survival (OS) of patients.

Reference materials:https://www.braftovi.com/